IP Library Granted Patent US 12,492,425
Granted Patent B2
US 12,492,425 · App. 17/416,681 · Granted Dec 9, 2025

Methods for RNA analysis

Inventors: Alexander Schwenger (Tübingen, DE); Stefan Heinz (Tübingen, DE); Tilmann Roos (Tübingen, DE); Benyamin Yazdan Panah (Tübingen, DE); Veronika Wagner (Tübingen, DE)
Assignee: CureVac SE
C12Q1/6806C12Q1/6813C12Q2521/30C12Q2523/107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,492,425
App. No.
17/416,681
Granted
Dec 9, 2025
Kind
B2
Abstract

The present invention is concerned with methods for analyzing RNA molecules. The provided methods involve conjugates for RNA cleavage comprising a chemical moiety with RNA cleaving activity and an oligonucleotide. The oligonucleotide is designed based on a target sequence present in an RNA molecule, and the cleavage of the RNA molecule is inter alia carried out at conditions allowing the hybridization of the oligonucleotide to the target 5 sequence. Thereby, the method is easily applicable to RNA molecules of any sequence. The method further involves the analysis of the RNA fragments obtained after cleavage to obtain information on the physical properties of the RNA molecule.

Claims (53)

1 . A method for analyzing an RNA molecule comprising the following steps:

(i) providing an RNA molecule;

(ii) providing at least one conjugate comprised of a chemical moiety with RNA cleaving activity and an oligonucleotide, wherein the sequence of said oligonucleotide is complementary to a target sequence of the RNA molecule;

(iii) cleaving the RNA molecule provided in step (i) to obtain RNA fragments by contacting the RNA molecule with the at least one conjugate provided in step (ii) under conditions allowing the hybridization of said oligonucleotide to said target sequence and the cleavage of the RNA molecule; and

(iv) determining a physical property of the RNA molecule by analyzing one or more of the RNA fragments obtained in step (iii),

wherein the RNA molecule is an mRNA molecule and comprises a 5′ cap structure and a PolyA sequence, wherein the conditions allowing the hybridization and the cleavage of the RNA molecule comprise one or more temperature shifts, wherein step (iii) of the method is as follows:

(iii) cleaving the RNA molecule provided in step (i) to obtain RNA fragments by contacting the RNA molecule with the conjugate provided in step (ii) at a first temperature between about 5° C. and about 50° C., and at a second temperature between about 70° C. and about 90° C.; followed by a step of repeating the above step (iii) at least once, wherein this step precedes step (iv).

2 . The method of claim 1 , wherein cleaving the RNA molecule results in a 5′ fragment, a 3′ fragment and optionally one or more central fragments.

3 . The method of claim 2 , wherein the fragments are separated from each other before analyzing the one or more of the RNA fragments in step (iv).

4 . The method of claim 3 , wherein the fragments are separated by chromatography.

5 . The method of claim 3 , wherein the fragments are separated by electrophoresis.

6 . The method of claim 3 , wherein the 5′ fragment is analyzed and/or the 3′ fragment is analyzed.

7 . The method of claim 6 , wherein the 5′ fragment is analyzed for one or more of

(i) presence and/or integrity of the cap structure,

(ii) methylation pattern; and

(iii) orientation,

by analytical HPLC and/or mass-spectrometry.

8 . The method of claim 6 , wherein the 5′ fragment has a length of 1 to 100 nucleotides.

9 . The method of claim 3 , wherein the 3′ fragment is analyzed.

10 . The method of claim 9 , wherein the 3′ fragment comprises the sequence.

11 . The method of claim 10 , wherein the 3′ fragment is analyzed for its nucleotide composition and/or length by complete hydrolysis of the 3′ fragment followed by analysis of the individual nucleotides gained thereby by analytical HPLC and/or mass spectrometry.

12 . The method of claim 10 , wherein the 3′ fragment has a length of 10 to 500 nucleotides.

13 . The method of claim 6 , wherein the RNA molecule is 300 to 9,000 nucleotides in length.

14 . The method of claim 1 , wherein the target sequence is present only once in the RNA molecule.

15 . A method for analyzing a population of RNA molecules comprising the following steps:

(i) providing a population of RNA molecules, wherein the population of RNA molecules comprises at least two different types of RNA molecules, wherein the different types of RNA molecules comprise an identical target sequence;

(ii) providing a conjugate comprised of a chemical moiety with RNA cleaving activity and an oligonucleotide, wherein the sequence of said oligonucleotide is complementary to the target sequence;

(iii) cleaving the population of RNA molecules provided in step (i) to obtain RNA fragments by contacting the RNA molecules with the conjugate provided in step (ii) under conditions allowing the hybridization of said oligonucleotide to said target sequence and the cleavage of the RNA molecules; and

(iv) determining a physical property of the RNA molecules in the population by analyzing one or more of the RNA fragments obtained in step (iii),

wherein the RNA molecules are mRNA molecules and each comprise a 5′ cap structure and/or a PolyA sequence, wherein the conditions allowing the hybridization and the cleavage of the RNA molecules comprises one or more temperature shifts, wherein step (iii) of the method is as follows:

(iii) cleaving the RNA molecules provided in step (i) to obtain RNA fragments by contacting the RNA molecules with the conjugates provided in step (ii) at a first temperature between about 5° C. and about 50° C., and at a second temperature between about 70° C. and about 90° C.; followed by a step of repeating the above step (iii) at least once, wherein this step precedes step (iv).

16 . A method for analyzing a population of RNA molecules comprising the following steps:

(i) providing a population of RNA molecules, wherein the population of RNA molecules comprises at least two different types of RNA molecules, wherein the different types of RNA molecules comprise different target sequences;

(ii) providing at least two conjugates comprised of a chemical moiety with RNA cleaving activity and an oligonucleotide, wherein the oligonucleotide sequence of each conjugate is complementary to one of the different target sequences;

(iii) cleaving the population of RNA molecules provided in step (i) to obtain RNA fragments by contacting the RNA molecules with the at least two conjugates provided in step (ii) under conditions allowing the hybridization of said oligonucleotides to said target sequences and the cleavage of the RNA molecules; and

(iv) determining a physical property of the RNA molecules in the population by analyzing one or more of the RNA fragments obtained in step (iii),

wherein the RNA molecules are mRNA molecules and each comprise a 5′ cap structure and/or a PolyA sequence, wherein the conditions allowing the hybridization and the cleavage of the RNA molecules comprises one or more temperature shifts, wherein step (iii) of the method is as follows:

(iii) cleaving the RNA molecules provided in step (i) to obtain RNA fragments by contacting the RNA molecules with the conjugates provided in step (ii) at a first temperature between about 5° C. and about 50° C., and at a second temperature between about 70° C. and about 90° C.; followed by a step of repeating the above step (iii) at least once, wherein this step precedes step (iv).

17 . The method of claim 4 , wherein the chromatography is HPLC.

18 . The method of claim 4 , wherein the chromatography is affinity chromatography.

19 . The method of claim 6 , wherein the sequence of said oligonucleotide is complementary to the target sequence of the RNA molecule over a length of 5-25 nucleotides.

20 . The method of claim 12 , wherein the wherein the 3′ fragment has a length 50 to 250 nucleotides.

21 . The method of claim 20 , wherein the RNA molecule is 300 to 9,000 nucleotides in length.

22 . The method of claim 21 , wherein the sequence of said oligonucleotide is complementary to the target sequence of the RNA molecule over a length of 5-25 nucleotides.

23 . The method of claim 22 , wherein the 3′ fragment is analyzed to determine PolyA length.

24 . The method of claim 23 , wherein the chemical moiety with RNA cleaving activity is tris (2-aminobenzimidazol), 1H-Imidazo[1,2-a]imidazole, 5H-Benzimidazo[1,2-a]benzimidazol, Hexahydro-2H-pyrimido[1,2a]pyrimidin-2,8-dion, 2-Aminobenzimidazol, Imidazo[1,2-a]benzimidazol, or 2-Aminochinolin.

25 . The method of claim 24 , wherein the chemical moiety with RNA cleaving activity is tris(2-aminobenzimidazole).

26 . The method of claim 6 , wherein the chemical moiety with RNA cleaving activity is tris(2-aminobenzimidazol), 1H-Imidazo[1,2-a]imidazole, 5H-Benzimidazo[1,2-a]benzimidazol, Hexahydro-2H-pyrimido[1,2a]pyrimidin-2,8-dion, 2-Aminobenzimidazol, Imidazo[1,2-a]benzimidazol, or 2-Aminochinolin.

27 . The method of claim 26 , wherein the chemical moiety with RNA cleaving activity is tris(2-aminobenzimidazole).

28 . The method of claim 15 , wherein the chemical moiety with RNA cleaving activity is tris(2-aminobenzimidazol), 1H-Imidazo[1,2-a]imidazole, 5H-Benzimidazo[1,2-a]benzimidazol, Hexahydro-2H-pyrimido[1,2a] pyrimidin-2,8-dion, 2-Aminobenzimidazol, Imidazo[1,2-a]benzimidazol, or 2-Aminochinolin.

29 . The method of claim 28 , wherein the chemical moiety with RNA cleaving activity is tris(2-aminobenzimidazole).

30 . The method of claim 16 , wherein the chemical moiety with RNA cleaving activity is tris(2-aminobenzimidazol), 1H-Imidazo[1,2-a]imidazole, 5H-Benzimidazo[1,2-a]benzimidazol, Hexahydro-2H-pyrimido[1,2a]pyrimidin-2,8-dion, 2-Aminobenzimidazol, Imidazo[1,2-a]benzimidazol, or 2-Aminochinolin.

31 . The method of claim 30 , wherein the chemical moiety with RNA cleaving activity is tris(2-aminobenzimidazole).

Assignments (2)
CHANGE OF NAME Recorded Dec 28, 2022
From: CUREVAC AG
To: CUREVAC SE
Reel/Frame 062248/0954 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2022
From: SCHWENGER, ALEXANDER; HEINZ, STEFAN; ROOS, TILMANN; YAZDAN PANAH, BENYAMIN; WAGNER, VERONIKA
To: CUREVAC AG
Reel/Frame 059983/0791 →
Continuity (1)
Related Publication 20220073962A1 · Mar 10, 2022
References Cited (134)
US 5594136A · Sessler et al. · 1997 [cited by applicant]
US 20050032730A1 · von der Mülbe et al. · 2005 [cited by applicant]
US 20050059624A1 · Hoerr et al. · 2005 [cited by applicant]
US 20050250723A1 · Hoerr et al. · 2005 [cited by applicant]
US 20060188490A1 · Hoerr et al. · 2006 [cited by applicant]
US 20070259830A1 · Karelson · 2007 [cited by examiner]
US 20080025944A1 · Hoerr et al. · 2008 [cited by applicant]
US 20080267873A1 · Hoerr et al. · 2008 [cited by applicant]
US 20090324584A1 · Hoerr et al. · 2009 [cited by applicant]
US 20100048883A1 · Ketterer et al. · 2010 [cited by applicant]
US 20100189729A1 · Hoerr et al. · 2010 [cited by applicant]
US 20100203076A1 · Fotin-Mleczek et al. · 2010 [cited by applicant]
US 20100291156A1 · Barner et al. · 2010 [cited by applicant]
US 20100305196A1 · Probst et al. · 2010 [cited by applicant]
US 20110053829A1 · Baumhof et al. · 2011 [cited by applicant]
US 20110250225A1 · Fotin-Mleczek et al. · 2011 [cited by applicant]
US 20120021043A1 · Kramps et al. · 2012 [cited by applicant]
US 20120258046A1 · Mutzke · 2012 [cited by applicant]
US 20130129754A1 · Thess et al. · 2013 [cited by applicant]
US 20130142818A1 · Baumhof et al. · 2013 [cited by applicant]
US 20130259879A1 · Baumhof et al. · 2013 [cited by applicant]
US 20130280283A1 · Lorenz et al. · 2013 [cited by applicant]
US 20130295043A1 · Kallen et al. · 2013 [cited by applicant]
US 20130336998A1 · Kallen et al. · 2013 [cited by applicant]
US 20150037326A1 · Butler-Ransohoff et al. · 2015 [cited by applicant]
US 20150050302A1 · Thess · 2015 [cited by applicant]
US 20150057340A1 · Thess et al. · 2015 [cited by applicant]
US 20150093413A1 · Thess et al. · 2015 [cited by applicant]
US 20150118183A1 · Baumhof · 2015 [cited by applicant]
US 20150118264A1 · Baumhof et al. · 2015 [cited by applicant]
US 20150165006A1 · Thess et al. · 2015 [cited by applicant]
US 20150184195A1 · Thess et al. · 2015 [cited by applicant]
US 20150218554A1 · Thess · 2015 [cited by applicant]
US 20150306249A1 · Baumhof et al. · 2015 [cited by applicant]
US 20150320847A1 · Thess et al. · 2015 [cited by applicant]
US 20160130345A1 · Fotin-Mleczek et al. · 2016 [cited by applicant]
US 20160166668A1 · Kallen et al. · 2016 [cited by applicant]
US 20160166678A1 · Kallen et al. · 2016 [cited by applicant]
US 20160166710A1 · Baumhof · 2016 [cited by applicant]
US 20160166711A1 · Schnee et al. · 2016 [cited by applicant]
US 20160168207A1 · Kramps et al. · 2016 [cited by applicant]
US 20160168227A1 · Kallen et al. · 2016 [cited by applicant]
US 20160235864A1 · Schlake et al. · 2016 [cited by applicant]
US 20160304883A1 · Grund et al. · 2016 [cited by applicant]
US 20160304938A1 · Wochner · 2016 [cited by applicant]
US 20160326575A1 · von der Mülbe · 2016 [cited by applicant]
US 20160331844A1 · Fotin-Mleczek et al. · 2016 [cited by applicant]
US 20170014496A1 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 20170029847A1 · Thess · 2017 [cited by applicant]
US 20170114378A1 · Wochner et al. · 2017 [cited by applicant]
US 20170252430A1 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 20170326225A1 · Rauch et al. · 2017 [cited by applicant]
US 20180044687A1 · Thess et al. · 2018 [cited by applicant]
US 20180125952A1 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 20180126003A1 · Hoerr · 2018 [cited by applicant]
US 20180142275A1 · Roos et al. · 2018 [cited by applicant]
US 20180147146A1 · Eber et al. · 2018 [cited by applicant]
US 20180148727A1 · Grund et al. · 2018 [cited by applicant]
US 20180201967A1 · Eber et al. · 2018 [cited by applicant]
US 20180208957A1 · Roos et al. · 2018 [cited by applicant]
US 20180214537A1 · Mutzke et al. · 2018 [cited by applicant]
US 20180237786A1 · Schlake et al. · 2018 [cited by applicant]
US 20180237817A1 · Roos et al. · 2018 [cited by applicant]
US 20180243219A1 · Ketterer et al. · 2018 [cited by applicant]
US 20180296663A1 · Hipp et al. · 2018 [cited by applicant]
US 20180298372A1 · Funkner et al. · 2018 [cited by applicant]
US 20180312545A1 · Baumhof et al. · 2018 [cited by applicant]
US 20180371392A1 · Mayer et al. · 2018 [cited by applicant]
US 20190010485A1 · Yazdan Panah et al. · 2019 [cited by applicant]
US 20190017100A1 · Wochner et al. · 2019 [cited by applicant]
US 20190024096A1 · Schmid et al. · 2019 [cited by applicant]
US 20190040378A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190049414A1 · Wochner et al. · 2019 [cited by applicant]
US 20190083602A1 · Roos et al. · 2019 [cited by applicant]
US 20190100784A1 · Eber et al. · 2019 [cited by applicant]
US 20190125857A1 · Rauch et al. · 2019 [cited by applicant]
US 20190133950A1 · Eber et al. · 2019 [cited by applicant]
US 20190160164A1 · Rauch et al. · 2019 [cited by applicant]
US 20190177714A1 · Kunze et al. · 2019 [cited by applicant]
US 20190185859A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190194760A1 · Koch et al. · 2019 [cited by applicant]
US 20190225971A1 · Williams · 2019 [cited by applicant]
US 20190241633A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190249219A1 · Reichert et al. · 2019 [cited by applicant]
US 20190336608A1 · Baumhof et al. · 2019 [cited by applicant]
US 20190336611A1 · Baumhof et al. · 2019 [cited by applicant]
US 20190343933A1 · Horscroft et al. · 2019 [cited by applicant]
US 20190343942A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190351044A1 · Jasny et al. · 2019 [cited by applicant]
US 20190351047A1 · Jasny et al. · 2019 [cited by applicant]
US 20190351048A1 · Rauch · 2019 [cited by applicant]
US 20190381180A1 · Baumhof et al. · 2019 [cited by applicant]
US 20200023076A1 · Fotin-Mleczek et al. · 2020 [cited by applicant]
US 20200085852A1 · Fotin-Mleczek · 2020 [cited by applicant]
US 20200085944A1 · Heidenreich et al. · 2020 [cited by applicant]
US 20200149026A1 · Horscroft et al. · 2020 [cited by applicant]
US 20200163878A1 · Baumhof et al. · 2020 [cited by applicant]
US 20200179526A1 · Baumhof et al. · 2020 [cited by applicant]
US 20200318097A1 · Funkner et al. · 2020 [cited by applicant]
US 20200392572A1 · Yazdan Panah et al. · 2020 [cited by applicant]
US 20210030864A1 · Petsch et al. · 2021 [cited by applicant]
US 20210069315A1 · Baumhof et al. · 2021 [cited by applicant]
US 20210162037A1 · Jasny et al. · 2021 [cited by applicant]
US 20210170017A1 · Lutz et al. · 2021 [cited by applicant]
US 20210180106A1 · Wochner et al. · 2021 [cited by applicant]
US 20210205434A1 · Petsch et al. · 2021 [cited by applicant]
US 20210260178A1 · Jasny et al. · 2021 [cited by applicant]
US 20210261897A1 · Yazdan Panah et al. · 2021 [cited by applicant]
US 20210361761A1 · Lutz et al. · 2021 [cited by applicant]
US 20210379181A1 · Rauch et al. · 2021 [cited by applicant]
US 20210403925A1 · Chevessier-Tünnesen et al. · 2021 [cited by applicant]
US 20220040281A1 · Schwendt et al. · 2022 [cited by applicant]
US 20220073962A1 · Schwenger et al. · 2022 [cited by applicant]
US 20220133908A1 · Rejman et al. · 2022 [cited by applicant]
US 20220144877A1 · Heinz et al. · 2022 [cited by applicant]
US 20220211838A1 · Oostvogels et al. · 2022 [cited by applicant]
US 20220233568A1 · Schlake et al. · 2022 [cited by applicant]
US 20220296628A1 · Thess et al. · 2022 [cited by applicant]
US 20220313813A1 · Rauch et al. · 2022 [cited by applicant]
US 20220340641A1 · Aggarwal et al. · 2022 [cited by applicant]
US 20230064106A1 · Heinz et al. · 2023 [cited by applicant]
WO WO2014152659 · 2014 [cited by applicant]
WO WO2017001058A1 · 2017 [cited by examiner]
WO WO2017098468 · 2017 [cited by applicant]
WO WO2021123332 · 2021 [cited by applicant]
WO WO2021254593 · 2021 [cited by applicant]
WO WO2022023559 · 2022 [cited by applicant]
WO WO2022043551 · 2022 [cited by applicant]
WO WO2022049093 · 2022 [cited by applicant]
Baker et al Nucleic Acids Research. 27(6): 1547-1551 (Year: 1999). [cited by examiner]
Danneberg et al., “Sequence-specific RNA cleavage by PNA conjugates of the metal-free artificial ribonuclease tris(2-aminobenzimidazole),” [cited by applicant]
Dogandzhiyski et al., “Studies on Tris(2-aminobenzimidazole)-PNA Based Artificial Nucleases: A Comparison of Two Analytical Techniques,” [cited by applicant]
Kuzuya et al., “Selective activation of two sites in RNA by acridine-bearing oligonucleotides for clipping of designated RNA fragments,” [cited by applicant]
PCT International Search Report and Written Opinion issued in International Application No. PCT/EP2019/086661, mailed Mar. 16, 2020. [cited by applicant]